• Consensus Rating: Buy
  • Consensus Price Target: $98.33
  • Forecasted Upside: 39.82 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$70.33
▲ +1.32 (1.91%)

This chart shows the closing price for LNTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lantheus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LNTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LNTH

Analyst Price Target is $98.33
▲ +39.82% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lantheus in the last 3 months. The average price target is $98.33, with a high forecast of $110.00 and a low forecast of $91.00. The average price target represents a 39.82% upside from the last price of $70.33.

This chart shows the closing price for LNTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Lantheus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/25/2022B. RileyReiterated RatingBuyLow
8/5/2022SVB LeerinkBoost TargetOutperform$100.00 ➝ $110.00Low
6/6/2022SVB LeerinkReiterated RatingOutperform$100.00High
5/9/2022B. RileyInitiated CoverageBuy$91.00High
5/2/2022Truist FinancialBoost Target$77.00 ➝ $94.00High
4/12/2022Truist FinancialInitiated CoverageBuy$77.00Medium
2/24/2022SVB LeerinkBoost TargetOutperform$34.00 ➝ $75.00High
10/22/2021SVB LeerinkReiterated RatingOutperformMedium
9/26/2021SVB LeerinkReiterated RatingBuyMedium
9/19/2021SVB LeerinkReiterated RatingBuyLow
7/29/2021SVB LeerinkBoost TargetOutperform$31.00 ➝ $34.00Low
5/5/2021Credit Suisse GroupBoost TargetNeutral$17.00 ➝ $20.00Low
4/28/2021SVB LeerinkBoost TargetOutperform$26.00 ➝ $31.00High
2/26/2021Credit Suisse GroupBoost TargetNeutral$14.00 ➝ $17.00High
2/26/2021SVB LeerinkBoost TargetOutperform$24.00 ➝ $25.00High
2/1/2021SVB LeerinkInitiated CoverageOutperform$24.00Low
12/29/2020Credit Suisse GroupLower TargetNeutral$16.00 ➝ $14.00N/A
6/29/2020Jefferies Financial GroupInitiated CoverageBuy$29.00High
6/16/2020CJS SecuritiesUpgradeMarket Perform ➝ OutperformMedium
8/16/2019CJS SecuritiesUpgradeMarket Perform ➝ OutperformHigh
8/2/2018Wells Fargo & CompanyLower TargetOutperform$26.00 ➝ $20.00High
8/2/2018Credit Suisse GroupLower TargetNeutral ➝ Neutral$23.00 ➝ $21.00High
11/3/2017Jefferies Financial GroupBoost TargetBuy$22.00 ➝ $27.00N/A
11/3/2017Credit Suisse GroupBoost TargetNeutral$19.00 ➝ $23.00N/A
11/2/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
10/12/2017Jefferies Financial GroupReiterated RatingBuy$22.00N/A
(Data available from 10/2/2017 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/6/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/5/2022
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 11 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
6/4/2022
  • 4 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/4/2022
  • 9 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
8/3/2022
  • 10 very positive mentions
  • 29 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
9/2/2022
  • 7 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
10/2/2022

Current Sentiment

  • 7 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Lantheus logo
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Read More

Today's Range

Now: $70.33
Low: $69.05
High: $72.75

50 Day Range

MA: $78.28
Low: $66.60
High: $86.60

52 Week Range

Now: $70.33
Low: $22.20
High: $87.47

Volume

1,134,490 shs

Average Volume

884,096 shs

Market Capitalization

$4.83 billion

P/E Ratio

163.56

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Lantheus?

The following Wall Street research analysts have issued reports on Lantheus in the last year: B. Riley, StockNews.com, SVB Leerink LLC, and Truist Financial Co..
View the latest analyst ratings for LNTH.

What is the current price target for Lantheus?

3 Wall Street analysts have set twelve-month price targets for Lantheus in the last year. Their average twelve-month price target is $98.33, suggesting a possible upside of 39.8%. SVB Leerink LLC has the highest price target set, predicting LNTH will reach $110.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $91.00 for Lantheus in the next year.
View the latest price targets for LNTH.

What is the current consensus analyst rating for Lantheus?

Lantheus currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LNTH will outperform the market and that investors should add to their positions of Lantheus.
View the latest ratings for LNTH.

What other companies compete with Lantheus?

How do I contact Lantheus' investor relations team?

Lantheus' physical mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider's listed phone number is (978) 671-8001 and its investor relations email address is [email protected] The official website for Lantheus is www.lantheus.com. Learn More about contacing Lantheus investor relations.